Insulin in endometrial carcinoma chemotherapy: A beneficial addition and not a problem
The effects of insulin or insulin in combination with chemotherapeutic drugs on the proliferation and apoptosis of endometrial carcinoma cells were examined with an aim to determine the efficacy and safety of insulin in endometrial cancer therapy. Ishikawa and Hec-1A cells were treated with insulin and/or paclitaxel. Cell proliferation was assessed by MTT assay. Cell cycle and cell apoptosis were determined by flow cytometry (FCM). Survivin gene expression was detected by RT-PCR. Our results showed that in a certain range of working concentrations and action time, insulin could mildly augment cell proliferation and the percentage of S phase cells in endometrial cancer (Ishikawa/Hec-1A) cells. Insulin plus paclitaxel (combination group) could significantly inhibit cell proliferation (69.38%±2.32% vs 40.31%±4.52% with Ishikawa; 64.11%±6.33% vs 45.89%±3.27% with Hec-1A) and increase cell apoptosis compared with treatment with paclitaxel alone (paclitaxel group). Survivin gene expression was also significantly decreased in combination group as compared with paclitaxel group. We are led to conclude that insulin can mildly augment cell proliferation and present chemotherapy sensitivity in endometrial cancer cells. Insulin can be to used safely and efficiently in endometrial cancer therapy.
Key wordsinsulin chemotherapy sensitivity endometrial cancer apoptosis proliferation cell cycle survivin
Unable to display preview. Download preview PDF.
- 1.American Cancer Society. Cancer Facts & Figures 2006. American Cancer Society, 2006Google Scholar
- 5.Zhao J, Xue FX, Hua SF, et al. Effects of insulin on proliferation and apoptosis of endometrial carcinoma cell. Zhonghua Fu Chan Ke Za Zhi (Chinese), 2007,42(10): 696–700Google Scholar
- 13.van Brussel JP, Oomen MA, Vossebeld PJ, et al. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU Int, 2004,93(9):1333–1338CrossRefPubMedGoogle Scholar